Steamboat Springs, CO, United States of America

Julia Grigorieva

USPTO Granted Patents = 23 (Patent Applications = 7)

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 9)

Average Co-Inventor Count = 3.6

ph-index = 8

Forward Citations = 214(Granted Patents)

Company Filing History:

University of Texas System

patents

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12230398 - Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods (2025-02-18),

2. 11621057 - Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy (2023-04-04),

3. 11150238 - Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups (2021-10-19),

4. 10950348 - Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods (2021-03-16),

5. 10217620 - Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry (2019-02-26),

6. 10037874 - Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry (2018-07-31),

7. 10007766 - Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods (2018-06-26),

8. 9824182 - Method and system for determining whether a drug will be effective on a patient with a disease (2017-11-21),

9. 9254120 - Method for predicting breast cancer patient response to combination therapy (2016-02-09),

10. 9152758 - Method and system for determining whether a drug will be effective on a patient with a disease (2015-10-06),

11. 8914238 - Method for predicting breast cancer patient response to endocrine therapy (2014-12-16),

12. 8718996 - Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents (2014-05-06),

13. 8586380 - Monitoring treatment of head and neck cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples (2013-11-19),

14. 8586379 - Monitoring treatment of colorectal cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples (2013-11-19),

15. 8119418 - Monitoring treatment of colorectal cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples (2012-02-21),

Title: Innovations by Julia Grigorieva: Pioneering Cancer Patient Prognosis

Introduction

Julia Grigorieva, a prominent inventor based in Steamboat Springs, Colorado, has made significant contributions to the field of cancer diagnostics and treatment. With an impressive portfolio of 23 patents, her work focuses on predictive methodologies that enhance patient outcomes in oncology, particularly in relation to immune checkpoint inhibitors and chemotherapy responses.

Latest Patents

Among her most recent patents are groundbreaking tests designed for predicting cancer patient responses. One notable invention is a predictive test aimed at determining patient benefits from an antibody drug that blocks ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein. This method utilizes mass spectrometry data from blood samples, integrating intensity values of various mass-spectral features to classify patients based on their likely response to treatment. The classification algorithm generates labels that predict the potential success of the antibody drug for patients, offering personalized treatment pathways.

Another significant patent involves the development of classifiers for assessing ovarian cancer patient prognosis under platinum chemotherapy. This method includes a systematic classifier generation process that categorizes clinical sub-groups based on patient data, thereby enhancing the accuracy of prognosis before treatment begins.

Career Highlights

Throughout her career, Julia has worked with leading organizations such as Biodesix, Inc. and the University of Texas System. Her endeavors in these institutions have solidified her reputation as an innovator in medical technology, particularly in the domain of oncological research.

Collaborations

Julia has collaborated with several notable professionals in her field, including Heinrich Röder and Maxim Tsypin. These partnerships have allowed her to expand her research capabilities and drive forward the development of her patented technologies.

Conclusion

Julia Grigorieva's contributions to cancer diagnostics and treatment through her innovative patents exemplify the potential of scientific research in significantly improving patient care. Her commitment to developing predictive tests and classifiers offers hope for more effective and personalized cancer therapies, marking her as a key figure in the realm of medical innovation.

This text is generated by artificial intelligence and may not be accurate.